Skip to main content
OpenTrials
Completed

NCT Number: NCT04245033

Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in Tanzania

In Tanzania, according to the National Malaria Control Programme (NMCP), malaria prevalence has declined from an average of 18.1% in 2008 to 7% in 2017, marked as an epidemiological transition from meso-endemic to hypo-endemic levels with variation across and within regions and/or councils. Children of school-age have become increasingly more vulnerable as compared to those aged less than five years. In high-transmission settings, up to 70% of school-aged children harbour malaria parasites which is mostly asymptomatic, accounting for around 50% of the mortality, 13-50% of all school absenteeism. The NMCP developed a supplementary malaria midterm strategic plan (SMMSP 2018-2020) to customise malaria interventions by stratifying the burden of malaria in Tanzania mainland and recommended use of Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) in high malaria strata. The investigators plan to evaluate the implementation of IPTsc using DP, given three times a year, for evidence on the operational feasibility and effectiveness of IPTsc on clinical malaria incidence at a high endemic area in Handeni District Council (DC), Handeni Town Council (TC) and Kilindi DC of Tanga region, Tanzania.

The study is an effectiveness-implementation hybrid trial to assess feasibility and effectiveness of IPTsc using DP against standard of care (control). Wards in the three study districts (Handeni DC, Handeni TC and Kilindi DC) will be the randomisation unit (clusters). Each ward will be randomised to implement IPTsc or not (control). In all wards in the IPTsc arm, the interventional drugs (DP) will be given at an interval of four months, three times a year. For study evaluation of the impact of intervention, in each district representative randomly selected wards, will provide randomly selected school per ward (24 in total) to formulate part of evaluable children per intervention. Mixed design methods will be used to assess the feasibility and acceptability of implementing IPTsc as part of a more comprehensive school children health package.

The study is expected to be operationally feasible given existing school health programme for Neglected Tropical Disease (NTD) control and the school net programme (SNP). IPTsc is expected to increase malaria case management effectiveness and to have additional effect in reducing the burden of disease on top of optimal access to malaria case management (MCM) and malaria vector control (MVC) initiatives e.g. early diagnosis and treatment, and insecticide-treated nets (ITNs) coverage, respectively.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–15 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Handeni Town Council, Handeni and Kilindi Districts

Tanga, Tanzania

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

The following eligibility criteria are used to enroll participants on for close monitoring follow ups assessing the effectiveness part of the study protocol.

Inclusion criteria

  • Includes parental/guardian informed consent
  • Assent by primary school children aged 11 years and above.
  • Aged 5-15 years.
  • Currently, lives within the pre-defined catchment area of study district; and
  • Will remain within the same area throughout the study period (preferably class five and below).

Exclusion criteria

  • Students at class 7
  • Currently enrolled in another study or participated in another investigational drug study within the last 30 days.
  • Known to have heart disease or a known cardiac ailment.
  • Reports known hypersensitivity to the study drugs.
  • Not willing to undergo all study procedures including physical examination and to provide blood samples as per this study protocol.
  • Having clinical features of severe anaemia
  • Febrile due to non-malaria illness at the time of recruitment.
  • Has apparent severe infection or any condition that requires hospitalization
  • Illness or conditions like hematologic, cardiac, renal, hepatic diseases which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study, including known G6PD deficiency and SS sickle cell.
  • Body weight < 12 kg

Treatment and study plan

Dihydroartemisinin-piperaquine (DP)

Drug

Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).

Primary outcomes

  1. Efficiency of school health teachers to deliver antimalarial drugs to school children in high endemic regions

    Time frame: 1 year from start of intervention

    Efficiency in terms of percentage of children given a complete dose in each round.

  2. Clinical malaria incidence

    Time frame: from month 0 till month 12 of follow up

    Malaria incidence will be collected in terms of number of episodes a child gets malaria.

Secondary outcomes

  1. Change in malaria incidence per 1000 population at local health facility level

    Time frame: from month 0 till month 12 of follow up

    Number of malaria episodes before and after intervention in a respective ward

  2. Change from baseline in haemoglobin concentration

    Time frame: measured at month 12

    individual change in Haemoglobin before and after intervention

  3. Number of participants with treatment-related adverse events

    Time frame: through study completion, an average of 1 year"

    Number of participants with treatment-related adverse events encountered by subjects per study arm

  4. Cardio safety profile by QTc prolongation from baseline

    Time frame: Day 1, 2,3 and 7 after before and after dosing

    measured by ECG

  5. Acceptability of IPTsc in communities with high malaria endemicities

    Time frame: At month 8 of implementation

    Through in depth interview in a guided questionnaire

Other outcomes

  1. Proportion of school children with malnutrition

    Time frame: at month 0 (baseline) and at month 12.

    Weight and height will be combined to report BMI in kg/m^2, WHO's BMI z-score will be used to categorise nutrition status.

Sponsors and collaborators

Lead sponsor

National Institute for Medical Research, Tanzania

Other Gov

Collaborators

  • National Malaria Control Program

Registry information

Acronym: IPTsc

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jan 28, 2020
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.